A psoriasis-specific model to support decision making in practice – UK experience

References

• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices – modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Øvretveit J. Does improving quality save money? A review of evidence of which improvements to quality reduce costs to health service providers. Internet document September 2009: Available from URL: http://www.health.org.uk/publications/research_reports/does_quality_save.html [Accessed 10 June 2010]
   Google Scholar
• Porter ME. A strategy for health care reform – toward a value-based system. N Engl J Med 2009;10:1056/NEJMpo904131
   Google Scholar
• Crisp N (2005). Commissioning a patient-led NHS. London: Department of Health. Available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4116717.pdf [Accessed 10 June 2010]
   Google Scholar
• Kennedy I. Appraising the value of innovation and other benefits. A short study for NICE. July 2009. Available at http://www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf [Accessed 10 June 2010]
   Google Scholar
• Cobden DS, Niessen LW, Barr CE, et al. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2009. Aug 20 (epub). Abstract available at URL: http://www.ncbi.nlm.nih.gov/pubmed/19695005 [Accessed 10 June 2010]
   Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15. Available at URL: http://www.bmj.com/cgi/reprint/333/7557/15 [Accessed 10 June 2010]
   Google Scholar
• Alitretinoin for the treatment of severe chronic hand eczema. Costing template and report implementing NICE guidance. NICE Technology Appraisal 177. August 2009 Available at: http://guidance.nice.org.uk/TA177/CostingTemplate/xls/English [Accessed 10 June 2010]
   Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Uttjek M, Dufåker M, Nygren L, et al. Determinants of quality of life in a psoriasis population in Northern Sweden. Acta Derm Venereol 2004;84:37-43
   PubMed Web of Science ®Google Scholar
• Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7
   PubMed Web of Science ®Google Scholar
• Poikolainen K, Reunala T, Karvonen J, et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990;300:780-3
   PubMed Web of Science ®Google Scholar
• Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3
   PubMed Web of Science ®Google Scholar
• Swanbeck G, Inerot A, Martinsson T, et al. A population genetic study of psoriasis. Br J Dermatol 1994;131:32-9
   PubMed Web of Science ®Google Scholar
• Morse RM, Perry HO, Hurt RD. Alcoholism and psoriasis. Alcohol Clin Exp Res 1985;9:396-9
   PubMed Web of Science ®Google Scholar
• Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
   PubMed Web of Science ®Google Scholar
• Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part 1): clinical update on antitumor necrosis factor agents. J Drugs Dermatol 2009;8:147-54
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Wahl A, Loge JH, Wiklund I, et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000;43:803-8
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Reboussin D, et al. Predictors of health-related quality of life in psoriasis and a comparison with other chronic diseases. Qual Life Res 1997;6:705
   Web of Science ®Google Scholar
• All Party Parliamentary Group on Skin. Report on the enquiry into the impact of skin diseases on people’s lives. London: APPG, July 2003
   Google Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213:102-10
   PubMed Web of Science ®Google Scholar
• Wu Y, Mills D, Bala M. Impact of psoriasis on patients’ work and productivity: a retrospective, matched case-control analysis. Am J Clin Derm 2009;10:407-10
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox, KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57:963-71
   PubMed Web of Science ®Google Scholar
• Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007;156:1245-50
   PubMed Web of Science ®Google Scholar
• Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-60
   PubMed Web of Science ®Google Scholar
• Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost of illness study. Dermatology 2006;212:137-44
   PubMed Web of Science ®Google Scholar
• Colombo GL, Altomare GF, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008;4:559-68
   PubMedGoogle Scholar
• Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and healthcare costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treat 2006;17:294-301
   PubMed Web of Science ®Google Scholar
• Traupe H, Robra B. Gesundheitsberichterstattung des Bundes. Heft 11: Psoriasis. Robert-Koch-Institut Berlin 2002
   Google Scholar
• Department of Health. Hospital Episode Statistics. L40 Psoriasis. HESonline primary diagnosis: 3 character 2008-2009. Diagnosis3_0709.xls. Available at http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=203 [Accessed 8 June 2010]
   Google Scholar
• Department of Health. National Schedule of Reference Costs. Elective inpatient HRG Data. Weighted average unit cost of currency codes JD02A, JD02B, JD02C (major skin disorder Category 1 with major CC, with intermediate CC, without CC, respectively). PBR_2007-08_NSRC04.xls. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945 [Accessed 10 June 2010]
   Google Scholar
• Conway P, Currie CJ. Descriptive epidemiology of hospitalisation for psoriasis. Curr Med Res Opin 2008;24:3487-91
   PubMed Web of Science ®Google Scholar
• Eedy DJ, Wootton R. Teledermatology: a review. Br J Dermatol 2001;144:696-707
   PubMed Web of Science ®Google Scholar
• Suneja T, Smith ED, Chen GJ, et al. Waiting times to see a dermatologist are perceived as too long by dermatologists. Implications for the Dermatology Workforce. Arch Dermatol 2001;137:1303-7
   PubMed Web of Science ®Google Scholar
• Cherry DK, Burt CW, Woodwell DA. National Ambulatory MEDICAL CARE Survey: 1999 Summary. Adv Data 2003 Aug 11;(337):1-44 [From Vital and Health Statistics] 2001;322:1-36
   Google Scholar
• Thompson TT, Feldman SR, Fleischer AB Jr. Only 33% of visits for skin disease in the US in 1995 were to dermatologists: is decreasing the number of dermatologists the appropriate response? Dermatol Online 1998;4:3
   PubMedGoogle Scholar
• Uttjek M, Dufåker M, Stenberg B, et al. Priority dilemmas in psoriasis care and visions of a future care in a group of administrators, politicians and professionals in northern Sweden. Health Policy 2008;87:203-16
   PubMed Web of Science ®Google Scholar
• Atopic eczema, psoriasis and acne: common chronic skin conditions that constitute a burden to general practice. A briefing paper prepared by Professor Carol Black, Professor David Gawkrodger and Dr Mark Goodfield on behalf of the Joint Specialty Committee for Dermatology. 14 February 2005. Available at: http://www.skincarecampaign.org/pages/SkinCareCampaignPolicy.htm [Accessed 10 June 2010]
   Google Scholar
• UK Coalition Government White Paper “Equity and Excellence: Liberating the NHS.” 12 July 2010, Department of Health. London. available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117353 (Accessed 18 August 2010)
   Google Scholar
• Imison C, Naylor C. Referral management. Lessons for success. 12 August 2010. The Kings Fund. Available at http://www.kingsfund.org.uk/publications/referral_management.html (Accessed 18 August 2010)
   Google Scholar
• Uttjek M, Dufåker M, Nygren L, et al. Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in Northern Sweden. Acta Dermatol Venereol 2005;85:503-8
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1
   PubMed Web of Science ®Google Scholar
• Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:581-8
   PubMed Web of Science ®Google Scholar
• Dermatology Workforce Group (2007). Models of integrated service delivery in dermatology. Available at http://www.skincarecampaign.org/pages/documents/Service%20Models%20Final%20(February%202007).pdf [last accessed 10 June 2010]
   Google Scholar
• Saurat J-H, Guérin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010;220:128-37
   PubMed Web of Science ®Google Scholar
• NICE. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. July 2006. Available at http://guidance.nice.org.uk/TA103/Guidance/pdf/English [last accessed 10 June 2010]
   Google Scholar
• Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol 2008;26:424-31
   PubMed Web of Science ®Google Scholar
• Cork M. Economic considerations in the treatment of psoriasis. Dermatology in Practice January/February 1993, pp16-20
   Google Scholar
• Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007;23:1887-901
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-3
   PubMed Web of Science ®Google Scholar
• Morton CA, Morais JC., Topical combination calcipotriol/betamethasone dipropionate prior to phototherapy in psoriasis – a cost-effective strategy? Presented at the European Academy of Dermatology and Venereology, Rhodes, 2006
   Google Scholar
• Academy of Managed Care Pharmacy. The AMCP format for formulary submissions (version 3.0). A format for submission of clinical and economic evidence of pharmaceuticals in support of formulary consideration. October 2009. Available at URL: http://www.amcp.org/format/pub.pdf [Accessed on 10 June 2010]
   Google Scholar
• Neumann PJ, Lin PJ, Greenberg D, et al. Do drug formulary policies reflect evidence of value? Am J Manage Care 2006;12:30-6
   PubMed Web of Science ®Google Scholar
• Jack A. No cure no cost. BMJ 2007;335:122-3
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: Innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm 2009;15:683-7
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5-26
   PubMed Web of Science ®Google Scholar
• O’Grady MJ, Capretta JC. Health-care cost projections for diabetes and other chronic diseases: the current context and potential enhancements. A White Paper commissioned by the Partnership to Fight Chronic Disease. May 2009. Internet Document Available at URL: http://www.fightchronicdisease.com/pdfs/CBO_whitepaperwPFCDback.pdf [Accessed 10 June 2010]
   Google Scholar
• Gray A, Clarke P, Farmer A, et al. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ 2002;325:860-5
   PubMed Web of Science ®Google Scholar
• CHMP, 18 November 2004: Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. Available at http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf [last accessed 10 June 2010]
   Google Scholar
• NICE Costing Template. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. July 2006. available at http://guidance.nice.org.uk/TA103/CostingReport/xls/English (accessed 10 June 2010)
   Google Scholar
• Updated guide to the methods of technology appraisal – June 2008. National Institute of health and Clinical Excellence. Available at available at http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp?domedia=1&mid=B52851A3-19B9-E0B5-D48284D172BD8459 [Accessed on 10 June 2010]
   Google Scholar
• Department of Health. The Year 2008/09. NHS Chief Executive’s Annual report 2008/09. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_099689 [last accessed 10 June 2010]
   Google Scholar
• Appelby J, Crawford R, Emmerson C. How cold will it be? Prospects for NHS funding 2011-2017. The Kings Fund, July 2009. Available at: http://www.kingsfund.org.uk/applications/research/index.rm?searchstring=How+cold+will+it+be%3F&filter=publications&id=20250&skip=0&sort=title&x=68&y=12 [last accessed 10 June 2010]
   Google Scholar
• Department of Health. The NHS in England: The operating framework for 2009/10. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445 [last accessed 10 June 2010]
   Google Scholar
• Best practice guidance for joint working between the NHS and the pharmaceutical industry, Department of Health, February 2008. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082370 [last accessed on 10 June 2010]
   Google Scholar
• Maroney M. Focus. Innovative pricing agreements to enhance access prospects. Pharma Pricing & Reimbursement 2009;14:238-43
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 129: Bortezomib monotherapy for relapsed multiple myeloma. 2007. 2007/056 NICE guidance on bortezomib (Velcade) is a win-win solution for multiple myeloma patients and the NHS. Available at: http://www.nice.org.uk/newsroom/pressreleases/2007056MultipleMyelomaPressRelease.jsp [Accessed on 10 June 2010]
   Google Scholar
• NICE technology appraisal 176. Cetuximab for the first-line treatment of metastatic colorectal cancer. Available at: http://guidance.nice.org.uk/TA176/Guidance/doc/English [Accessed 10 June 2010]
   Google Scholar
• NICE technology appraisal 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. August 2008. Available at: http://guidance.nice.org.uk/TA155/Guidance/pdf/English [Accessed on 10 June 2010]
   Google Scholar
• NICE technology appraisal 180. Ustekinumab for the treatment of adults with moderate to severe psoriasis. September 2009. Available at: http://guidance.nice.org.uk/TA180/Guidance/doc/English [Accessed 10 June 2010]
   Google Scholar
• Shearer L. CIGNA and Merck sign performance-based contract. Cigna news release. 23 April 2009. Available at: http://newsroom.cigna.com/article_display.cfm?article_id=1043 [Accessed 10 June 2010
   Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom. Arch Dermatol 2005;141:1537-41
   PubMed Web of Science ®Google Scholar
• Gillard SE, Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. Int J Clin Pract 2005;59:1260-7
   PubMed Web of Science ®Google Scholar
• Peeters P, Ortonne J-P, Sitbon R, et al. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139-145
   PubMed Web of Science ®Google Scholar
• Dawe, R Wainwright NJ, Cameron H, et al. Narrow band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833-9
   PubMed Web of Science ®Google Scholar
• MIMS June 2010
   Google Scholar
• Curtis L. Unit Costs of Health & Social Care. 2009. PSSRU University of Kent. 2009. 11.7 min clinical consultation. Available at: http://www.pssru.ac.uk/pdf/uc/uc2009/uc2009.pdf [accessed 10 June 2010]
   Google Scholar